Evaluación positiva de medicamentosjunio/julio 2013

  1. P. Álvarez Herranz
  2. P. Prats Olivan
  3. M. Puerro Vicente
  4. A. García Luque
Revista:
Sanidad militar: revista de sanidad de las Fuerzas Armadas de España

ISSN: 1887-8571

Año de publicación: 2013

Volumen: 69

Número: 4

Páginas: 260-265

Tipo: Artículo

DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Sanidad militar: revista de sanidad de las Fuerzas Armadas de España

Resumen

The drugs assessed by the Spanish Agency for Medicines and Health Products made public in June and July of 2013, and considered of interest in hospital healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

Referencias bibliográficas

  • EMA 377379/2013.
  • Informe mensual sobre Medicamentos de Uso Humano y Productos Sanitarios Junio 2013.
  • (2008). Alemtuzumab vs. interferon beta la in early multiple sclerosis. N Engl J Med. 359. 1786
  • Coles, AJ, twyman, CL. (2012). Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomized controlled phase 3 trial. The lancet. 380. 1819
  • Cohen, JA, Coles, AJ. (2012). Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomized controlled phase 3 trial. The Lancet. 380. 1829
  • EMA 447957/2013.
  • Informe mensual sobre Medicamentos de Uso Humano y Productos Sanitarios Julio 2013.
  • Hirsh, V, Cadranel, J. (2013). Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of arandomized phase IIb/III trial (LUX-Lung 1). J Thorac Oncol. 8. 229
  • EMA 229786/2013.
  • EMA 223982/2013.
  • Seino, Y, Miyata, Y, Hiroi, S, Hirayama, M, Kaku, K. (2012). Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. Diabetes Obes Metab. 14. 927
  • EMA 229752/2013.
  • Pratley, Re, Reusch, JE. (2009). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 25. 2361
  • DeFronzo, RA, Burant, CF. (2012). Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab. 97. 1615
  • EMA/CHMP/363851/2013.
  • EMA/CHMP/413499/2013.
  • EMA/CHMP/339899/2013.
  • Hauschild, A, Grob, JJ. (2012). Dabrafenib in BRAF-mutated metastasic melanoma: a multicentre, open-label, phase 3 randomized controlled trial. The Lancet. 380. 358
  • EMA 455080/2013.
  • EMA 380955/2013.
  • EMA/CHMP/385035/2013.
  • EMA/CHMP/304525/2013.
  • EMA/422789/2013.
  • EMA/CHMP/347765/2013.
  • EMA/CHMP/457182/2013.
  • Chapman, KR, Rennard, SI, Dogra, A, Owen, R, Lassen, C, Kramer, B. (2011). Long-term safety and efficacy of indacaterol, a long-acting b2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 140. 68-75
  • EMA/CHMP/363689/2013.
  • EMA/CHMP/364710/2013.
  • EMA /358125/2013.
  • Grothey, A, Van Cutsem, E. (2013). Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomized, placebo-controlled, phase 3 trial. Lancet. 381. 303
Fuente de los datos: Dialnet